Search

Displaying all 8 results
DrugBest match

Nilotinib

go.drugbank.com/drugs/DB04868
ApprovedInvestigational

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant ...

  1. Pathway

    Nilotinib Predicted Metabolism Pathway

    smpdb.ca/view/SMP0174600
    Metabolic

    Metabolites of Nilotinib are predicted with biotransformer.

    Drugs: Mesoheme · Nilotinib
  2. Pathway

    Nilotinib Inhibition of BCR-ABL Action Pathway

    smpdb.ca/view/SMP0031697
    Drug action

    Notably, Nilotinib is ineffective against the T315I mutation in BCR-ABL, and further research is necessary. … Nilotinib is able to bind ABL with greater affinity than Imatinib (20-fold to 30-fold increase). It is therefore administered to patients with Imatinib resistance.

    Drugs: Nilotinib
  3. Indication

    Refractory Gastrointestinal stromal tumor

    go.drugbank.com/conditions/DBCOND0023195
    Drugs: Nilotinib
  4. Indication

    Newly diagnosed, chronic phase Chronic myeloid leukemia

    go.drugbank.com/conditions/DBCOND0021945
    Drugs: Asciminib · Imatinib · Nilotinib
  5. Indication

    Accelerated Phase Chronic Myelogenous Leukemia (CML)

    go.drugbank.com/conditions/DBCOND0121922
    Drugs: Bosutinib · Dasatinib · Imatinib · Nilotinib · Ponatinib
  6. Indication

    Chronic Phase Chronic Myeloid Leukemia

    go.drugbank.com/conditions/DBCOND0057382
    Drugs: Asciminib · Bosutinib · Dasatinib · Daunorubicin · Nilotinib · Ponatinib
  7. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those that target the inactive kinase domain ([imatinib], [nilotinib

    Categories: Nicotinic Acids